Article
MetaVia Reports Phase 1b Clinical Trial Results Of DA-1726
Statistically Significant (p=0.006) Waist Circumference Reduction of 9.8 cm at Day 54
Significant Direct Hepatic Activity with a 23.7% Reduction in Liver Stiffness (VCTE) by Day 54
Strong Glycemic Response with a 12.3 mg/dL Fasted Glucose Reduction by Day 54
Robust Weight Loss with 9.1% Reduction (21.2 lbs) by Day 54
Comments
- No comments yet. Be the first to comment!